Micrornas in non-small cell lung cancer: Current status and future therapeutic promises

Current Pharmaceutical Design

Volumn 20, Issue 24, 2014, Pages 3982-3990

  Cortinovis, D ^a   Monica, V ^b   Pietrantonio, F ^c   Ceresoli, G L ^d   la Spina, C M ^d   Wannesson, L ^e  

^a Oncology Unit San Gerardo Hospital   (Switzerland)

^b UNIVERSITY OF TURIN   (Italy)

^c Oncology Unit Istituto Nazionale per la Cura dei Tumori   (Switzerland)

^d Humanitas Gavazzeni Hospital   (Italy)

^e ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

MiRNA; NSCLC; Predictive; Prognostic; Therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; MICRORNA; MICRORNA 221; PACLITAXEL; SMALL INTERFERING RNA;

CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; GENE EXPRESSION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NANOBIOTECHNOLOGY; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SCREENING; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; METABOLISM;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MICRORNAS;

EID: 84903995989     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660755     Document Type: Review

References (102)

1. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006 Apr;6(4): 259-269.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1): 57-70.
3. Landi MT, Zhao Y, Rotunno M, et al: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010;16: 430-441.
4. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009; 69: 5776-5783.
5. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
6. Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011 Apr 1;17(7): 1875-1882.
7. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9): 3713-3718.
8. Shen J, Todd NW, Zhang H, et al: Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011;91: 579-587.
9. Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival in non-small-cell lung cancer. J Clin Oncol 2010; 28: 225-249.
10. Ceppi P, Mudduluru G, Kumashrwamy R, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer Mol Cancer Res. 2010 Sep;8(9): 1207-1216.
11. Weiss GJ, Bemis LT, Nakajima E, et al. EGFR regulation by mi-croRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008; 19: 1053-1059.
12. Webster RJ, Giles KM, Price KJ, et al. Regulation of epidermal growth factor receptor signaling in human cancer cells by mi-croRNA-7J Biol Chem. 2009 Feb 27;284(9): 5731-5741.
13. Liu XI, Sempere LF, Guo Y, et al. Involvement of microRNAs in lung cancer biology and therapy. Transl Res. 2011 Apr;157(4): 200-208.
14. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005 Mar 11;120(5): 635-647.
15. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007 Jun 28;447(7148): 1130-1134.
16. Liu B, Pneg XC, Zheng XL, et al. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009 Nov;66(2): 169-175.
17. Crawford M, Brawner E, Batte K, et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Bio-phys Res Commun. 2008 Sep 5;373(4): 607-612.
18. Lee R.C, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993 Dec 3;75(5): 843-854.
19. Lewis BP, Shih IH, Jones-Rohades MW, et al. Prediction of mammalian microRNA targets Cell. 2003 Dec 26;115(7): 787-798.
20. Chen CZ, Li L, Lodish HF, et al. MicroRNAs modulate hema-topoietic lineage differentiation. Science. 2004 Jan 2;303(5654): 83-86.
21. Hwang H.W. Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis Br J Cancer. 2006 Mar 27;94(6): 776-780.
22. Osaki M, Takeshita F, Ochiva T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers. 2008 Nov;13(7): 658-670.
23. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science. 2001 Oct 26;294(5543): 853-858.
24. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001 Oct 26;294(5543): 862-864.
25. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116: 281-297.
26. Babiarz JE, Ruby JC, Wang Y, et al. Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. Genes Dev. 2008 Oct 15;22(20): 2773-2785.
27. Berezikov E, Chung WJ, Willis J, et al. Mammalian mirtron genes. Mol Cell. 2007 Oct 26;28(2): 328-336.
28. Slack F, Widhaas JB. MicroRNA in cancer prognosis. N Engl J Med. 2008 Dec 18;359(25): 2720-2722.
29. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients Cancer Sci. 2005 Feb;96(2): 111-115.
30. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756.
31. Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007 May;39(5): 673-677.
32. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010 Sep 14;18(3): 282-293.
33. Lewis BP, Shih IH, Jones-Rhoades MW et al. Prediction of mammalian microRNA targets. Cell. 2003 Dec 26;115(7): 787-798.
34. Grimson A, Farh KK, Johnson WK et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol.Cell, 2007 Jul 6;27(1): 91-105
35. Ritchie W, Flamant S, Rasko JE. Predicting microRNA targets and functions: traps for the unwary. Nat Methods. 2009 Jun;6(6): 397-398
36. Kuhn DE, Martin MM, Feldman DS et al. Experimental validation of miRNA targets. Methods. 2008 Jan;44(1): 47-54.
37. Elmén J, Lindow M, Schütz S et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008 Apr 17;452(7189): 896-899.
38. Krützfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005 Dec 1;438(7068): 685-689
39. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007 Sep;4(9): 721-726.
40. Haraguchi T, Ozaki Y, Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009 Apr;37(6): e43.
41. Xu G, Fewell C, Taylor C et al. Transcriptome and targetome analysis in MIR155 expressing cells using RNA-seq. RNA. 2010 Aug;16(8): 1610-1622.
42. Zhang Y, Xu B, Yang Y, Cooke HJ et al. CPSS: A computational platform for the analysis of small RNA deep sequencing data. Bio-informatics. 2012 May 9.
43. Hafner M, Landthaler M, Burger L et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010 Apr 2;141(1): 129-141.
44. Selbach M, Schwanhäusser B, Thierfelder N et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008 Sep 4;455(7209): 58-63.
45. Baek D, Villén J, Shin C et al. The impact of microRNAs on protein output. Nature. 2008 Sep 4;455(7209): 64-71.
46. Jørgensen S, Baker A, Møller S et al. Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods. 2010 Dec;52(4): 375-381.
47. Hunter MP, Ismail N, Zhang X, et al: Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3: e3694.
48. Rabinowits G, Gercel-Taylor C, Day JM, et al: Exosomal mi-croRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10: 42-46.
49. Foss KM, Sima C, Ugolini D, et al. miR-1254 and miR-574- 5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J. Thorac. Oncol.2011; 6: 482-488
50. Roa WH, Kim JO, Razzak R, et al. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin Invest Med 2012;35: E271
51. Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 2012;7: e32307
52. Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4: 575-586.
53. Bishop JA, Benjamin H, Cholakh H, et al: Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16: 610-619
54. Du L, Schageman JJ, Irnov, et al: MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res 29: 75
55. Gilad S, Lithwick-Yanai G, Barshack I, et al. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn 2012;14: 510-517
56. Navarro A, Diaz T, Gallardo E, et al. Prognostic implications of miR-16 expression levels in resected non-small cell lung cancer. J Surg Oncol. 2011; 103: 411-415.
57. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic Value of Mature MicroRNA-21 and MicroRNA-205 Overexpression in Non-Small Cell Lung Cancer by Quantitative Real-Time RT- PCR. Clinical Chemistry 2008; 54: 1696-1704.
58. Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis Biomed Pharmacother 2010; 64: 399-408.
59. Duncavage E, Goodgame B, Sezhiyan A, et al. Use of MicroRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer J Thorac Oncol 2010; 5: 1755-1763.
60. Saito M, Schetter AJ, Mollerup S, et al. The association of mi-croRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011; 17: 1875-1882.
61. Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2012 Oct 22 [Epub ahead of print]
62. Inamura K, Togashi Y, Nomura K, et al. Let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer 2007; 58: 392-396.
63. Donnem T, Eklo K, Berg T, et al. Prognostic impact of miRNA-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med 2011; 9: 6.
64. Donnem T, Lonvik K, Eklo K, et al. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: Coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011; 117: 3193-3200.
65. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer cell 2008; 13: 48-57.
66. Patnaik SK, Kannisto E, Knudsen S, et al. Evaluation of mi-croRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010; 70: 36-45.
67. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2: 48-58.
68. Nana-Sinkam SP, Fabbri M, Croce CM. MicroRNAs in cancer: personalizing diagnosi and therapy. Ann N Y Acad Sci 2010;1210: 25-33.
69. Giovanetti E, Erozenci A, Smit J, et al. Molecular mechanism underlying the role of micro-RNAs (miRNAs) in anticancer drug resistance and implication for clinical practice. Crit Rev Oncol Hematol 2011; May 4 [Epub ahead of print].
70. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nature Reviews Cancer 2010;10: 389-402.
71. Megiorni F, Pizzuti A, Frati L. Clinical significance of microRNA expression profiles and polymorphisms in lung cancer development and management. Pathology Research International 2011; Jul 27 [Epub ahead of print].
72. Blower PE, Verducci JS, Lin S, et al. microRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007;6: 1483-1491.
73. Enfield KS, Stewart GL, Pikor LA, et al. MicroRNA gene dosage alterations and drug response in lung cancer. J Biomed Biotechnol 2011; Mar 31 [Epub ahead of print].
74. Galluzzi L, Morselli E, Vitale I, et al. MiR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70: 1793-1803.
75. Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011;30: 407-414.
76. Voortman J, Goto A, Mendiboure J, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010;70: 8288-8298.
77. Gao W, Lu X, Liu L, et al. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012;13: 330-340.
78. Xie L, Chen X, Wang L, et al. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 2010;10: 591-596.
79. Holleman A, Chung I, Olsen RR, et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Onco-gene 2011;May 9 [Epub ahead of print].
80. Du L, Subauste MC, DeSevo C, et al. MiR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012;7: e39167.
81. Feng B, Wang R, Chen LB. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 2012;317: 184-191
82. Feng B, Wang R, Song HZ et al. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarci-noma cells by targeting E2F3. Cancer 2012;118: 3365-3376
83. Bryant JL, Britson J, Balko JM, et al. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer 2012;106: 148-156
84. Ceppi P, Mudduluru G, Kumarswamy R, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010;8: 1207-1216
85. Oh JS, Kim JJ, Byun JY, Kim IA. Lin28-let7 modulates radiosensi-tivity of human cancer cells with activation of kRAS. Int J Radiation Oncology boil phys 2010;76: 5-8.
86. Salim H, Akbar NS, Zong D et al. MiRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer 2012;107: 1361-1373
87. Markou A, Liang Y, Lianidou E. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clin Chem Lab Med 2011; Jul 18 [Epub ahead of print].
88. Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of mi-croRNA-122 in mice by systemically administered LNAantimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008;36: 1153-1162.
89. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452: 896-899.
90. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of micro-RNAs in vivo with 'antagomirs'. Nature 2005;438: 685-689.
91. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103: 2257-2261.
92. Ebert MS, Neilson JR, Sharp PA: MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007, 4: 721-726.
93. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 mi-croRNA represses cell proliferation pathways in human cells. Cancer Res 2007, 67: 7713-7722.
94. Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007,67: 1111-1116.
95. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120: 1298-1309.
96. Zenz T, Mohr J, Eldering E, et al. MiR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009;113: 3801-3808.
97. Liu X, Sempere LF, Galimberti F, et al. Uncovering growthsup-pressive MicroRNAs in lung cancer. Clin Cancer Res 2009;15: 1177-1183.
98. Wiggins JF, Ruffino L, Kelnar K, et al. Development of a Lung Cancer Therapeutic Based on the tumor Suppressor MicroRNA-34. Cancer Res 2010;70: 5923-5930.
99. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Onco-gene 2008; 27: 3845-3855.
100. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Onco-gene 2007; 26: 2799-2803.
101. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-433.
102. Zhong M, Ma X, Sun C, et al. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chemico-Biological Interactions 184 (2010) 431-438.